Ubiquibody platform for targeted degradation of oncogenic fusion proteins
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91023C00010
- Awardee
-
Ubiquitx Inc. UEI LRA7LGJCZP15
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $354,908
Award facts
- Opportunity
-
- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2023 Pre-Solicitation · 75N91022R00006 · Posted Feb 10, 2022
- Contract value 100% obligated
- $354,908.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 17 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10024, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $55,000 | |
| Other Administrative Action | $0 | |
| Original award | $299,908 |
About this award
This $354,908 firm fixed price definitive contract was awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Ubiquitx Inc., a New York-based for-profit small business. The contract is for the development of the Ubiquibody Platform for Targeted Degradation of Oncogenic Fusion Proteins, as initially solicited under the Institute's Small Business Innovation Research Innovative Concept Award Program. This total small business set-aside award will support Ubiquitx's efforts to demonstrate technical feasibility and proof-of-concept for its therapeutic technology, which aims to facilitate the targeted degradation of pediatric and rare cancer-causing fusion proteins. Work will be performed in New York through February 2025.
Quick answers
Who was awarded contract 75N91023C00010?
75N91023C00010 was awarded to Ubiquitx Inc. by National Cancer Institute (National Institutes of Health) on February 27, 2023.
How much is contract 75N91023C00010 worth?
The government has obligated $354,908 on 75N91023C00010.
Was contract 75N91023C00010 competed?
The extent of competition for 75N91023C00010 was full and open competition after exclusion of sources. The government received 17 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award